{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:16Z","timestamp":1792785076957,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":109,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangzhou Health Technology Project","award":["20231A011012"],"award-info":[{"award-number":["20231A011012"]}]},{"name":"Guangzhou Health Technology Project","award":["20231A011012"],"award-info":[{"award-number":["20231A011012"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFA1800103"],"award-info":[{"award-number":["2023YFA1800103"]}]},{"name":"National Natural Science Foundation of China","award":["82400204"],"award-info":[{"award-number":["82400204"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangzhou Municipal Science and Technology Project","award":["2024A03J1022"],"award-info":[{"award-number":["2024A03J1022"]}]},{"name":"GuangDong Basic and Applied Basic Research Foundation","award":["2025A1515010062"],"award-info":[{"award-number":["2025A1515010062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01550-7","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:17:30Z","timestamp":1781950650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGI-7079 as a novel type I FLT3 inhibitor overcomes resistance to gilteritinib and quizartinib mediated by ITD and TKD mutations in acute myeloid leukemia"],"prefix":"10.1038","volume":"10","author":[{"given":"Zhiwei","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miner","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingfen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"1550_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","volume":"368","author":"E Estey","year":"2006","unstructured":"Estey, E. & Dohner, H. Acute myeloid leukaemia. Lancet 368, 1894\u20131907 (2006).","journal-title":"Lancet"},{"key":"1550_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1550_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali, R. S., Pratz, K. W. & Lai, C. Recent advances in targeted therapies in acute myeloid leukemia. J. Hematol. Oncol. 16, 29 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1550_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H. et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 11, 41 (2021).","journal-title":"Blood Cancer J."},{"key":"1550_CR5","doi-asserted-by":"crossref","unstructured":"Frohling, S. et al. Leukemia AMLSGUAm: prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100, 4372\u20134380 (2002).","DOI":"10.1182\/blood-2002-05-1440"},{"key":"1550_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03368-4","volume":"24","author":"N Kim","year":"2024","unstructured":"Kim, N. et al. Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes. Cancer Cell Int. 24, 174 (2024).","journal-title":"Cancer Cell Int."},{"key":"1550_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland, D. G. & Griffin, J. D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100, 1532\u20131542 (2002).","journal-title":"Blood"},{"key":"1550_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","volume":"13","author":"J Griffith","year":"2004","unstructured":"Griffith, J. et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13, 169\u2013178 (2004).","journal-title":"Mol. Cell"},{"key":"1550_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood-2006-05-024018","volume":"110","author":"C Choudhary","year":"2007","unstructured":"Choudhary, C. et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110, 370\u2013374 (2007).","journal-title":"Blood"},{"key":"1550_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-4-13","volume":"4","author":"S Takahashi","year":"2011","unstructured":"Takahashi, S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J. Hematol. Oncol. 4, 13 (2011).","journal-title":"J. Hematol. Oncol."},{"key":"1550_CR11","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede, C. et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99, 4326\u20134335 (2002).","journal-title":"Blood"},{"key":"1550_CR12","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto, Y. et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97, 2434\u20132439 (2001).","journal-title":"Blood"},{"key":"1550_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2012.191","volume":"27","author":"AB Williams","year":"2013","unstructured":"Williams, A. B. et al. Mutations of FLT3\/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 27, 48\u201355 (2013).","journal-title":"Leukemia"},{"key":"1550_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33, 299\u2013312 (2019).","journal-title":"Leukemia"},{"key":"1550_CR15","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","volume":"111","author":"U Bacher","year":"2008","unstructured":"Bacher, U., Haferlach, C., Kern, W., Haferlach, T. & Schnittger, S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood 111, 2527\u20132537 (2008).","journal-title":"Blood"},{"key":"1550_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","volume":"13","author":"MT Gebru","year":"2020","unstructured":"Gebru, M. T. & Wang, H. G. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J. Hematol. Oncol. 13, 155 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1550_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.critrevonc.2019.06.011","volume":"141","author":"TM Weis","year":"2019","unstructured":"Weis, T. M., Marini, B. L., Bixby, D. L. & Perissinotti, A. J. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit. Rev. Oncol. Hematol. 141, 125\u2013138 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1550_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","volume":"11","author":"M Wu","year":"2018","unstructured":"Wu, M., Li, C. & Zhu, X. FLT3 inhibitors in acute myeloid leukemia. J. Hematol. Oncol. 11, 133 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"1550_CR19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl, A. E. et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 18, 1061\u20131075 (2017).","journal-title":"Lancet Oncol."},{"key":"1550_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","volume":"17","author":"J Cortes","year":"2024","unstructured":"Cortes, J. Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. J. Hematol. Oncol. 17, 111 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1550_CR21","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1200\/JCO.23.01061","volume":"42","author":"ES Wang","year":"2024","unstructured":"Wang, E. S. et al. Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML. J. Clin. Oncol. 42, 1776\u20131787 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1550_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon, S. Gilteritinib: first global approval. Drugs 79, 331\u2013339 (2019).","journal-title":"Drugs"},{"key":"1550_CR23","doi-asserted-by":"publisher","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao, J. C. et al. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 52, 100905 (2022).","journal-title":"Blood Rev."},{"key":"1550_CR24","doi-asserted-by":"crossref","unstructured":"Eguchi M., Minami Y., Kuzume A., & Chi S. Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia. Biomedicines 8, 245 (2020).","DOI":"10.3390\/biomedicines8080245"},{"key":"1550_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08263-x","volume":"10","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat. Commun. 10, 244 (2019).","journal-title":"Nat. Commun."},{"key":"1550_CR26","doi-asserted-by":"publisher","first-page":"204209862412841","DOI":"10.1177\/20420986241284105","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS). Ther. Adv. Drug Saf. 15, 20420986241284105 (2024).","journal-title":"Ther. Adv. Drug Saf."},{"key":"1550_CR27","doi-asserted-by":"publisher","first-page":"1294668","DOI":"10.3389\/fphar.2024.1294668","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid malignancies: a systemic analysis of clinical trials. Front. Pharm. 15, 1294668 (2024).","journal-title":"Front. Pharm."},{"key":"1550_CR28","doi-asserted-by":"crossref","unstructured":"Mukherjee, S. et al. Synergistic inhibition of drug resistant KRAS mutant non-small cell lung cancer by co-targeting AXL and SRC. Cancers 17, 490 (2025).","DOI":"10.3390\/cancers17030490"},{"key":"1550_CR29","doi-asserted-by":"publisher","first-page":"6516","DOI":"10.1158\/0008-5472.CAN-13-0967","volume":"73","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res. 73, 6516\u20136525 (2013).","journal-title":"Cancer Res."},{"key":"1550_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279\u2013290 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1550_CR31","doi-asserted-by":"publisher","first-page":"117788","DOI":"10.1016\/j.biopha.2024.117788","volume":"182","author":"J Rataj","year":"2025","unstructured":"Rataj, J. et al. Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: novel molecular approaches and therapeutic challenges. Biomed. Pharmacother. 182, 117788 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"1550_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian, H. et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 14, 163 (2024).","journal-title":"Blood Cancer J."},{"key":"1550_CR33","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1182\/blood-2007-05-092510","volume":"111","author":"A Sallmyr","year":"2008","unstructured":"Sallmyr, A. et al. Internal tandem duplication of FLT3 (FLT3\/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 111, 3173\u20133182 (2008).","journal-title":"Blood"},{"key":"1550_CR34","doi-asserted-by":"publisher","first-page":"104424","DOI":"10.1016\/j.critrevonc.2024.104424","volume":"201","author":"M Ruglioni","year":"2024","unstructured":"Ruglioni, M. et al. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. Crit. Rev. Oncol. Hematol. 201, 104424 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1550_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.7150\/thno.46593","volume":"11","author":"Z Yu","year":"2021","unstructured":"Yu, Z. et al. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. Theranostics 11, 93\u2013106 (2021).","journal-title":"Theranostics"},{"key":"1550_CR36","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1158\/1078-0432.CCR-13-1323","volume":"19","author":"SD Baker","year":"2013","unstructured":"Baker, S. D. et al. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin. Cancer Res. 19, 5758\u20135768 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1550_CR37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","volume":"16","author":"M Larrosa-Garcia","year":"2017","unstructured":"Larrosa-Garcia, M. & Baer, M. R. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol. Cancer Ther. 16, 991\u20131001 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"1550_CR38","doi-asserted-by":"crossref","unstructured":"Lam, S. S. Y. & Leung, A. Y. H. Overcoming resistance to FLT3 inhibitors in the treatment of FLT3-mutated AML. Int. J. Mol. Sci. 21, 1537 (2020).","DOI":"10.3390\/ijms21041537"},{"key":"1550_CR39","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","volume":"4","author":"M Levis","year":"2020","unstructured":"Levis, M. & Perl, A. E. Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv. 4, 1178\u20131191 (2020).","journal-title":"Blood Adv."},{"key":"1550_CR40","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/0008-5472.CAN-23-1534","volume":"84","author":"P Wang","year":"2024","unstructured":"Wang, P. et al. Foretinib is effective in acute myeloid leukemia by inhibiting FLT3 and overcoming secondary mutations that drive resistance to quizartinib and gilteritinib. Cancer Res. 84, 905\u2013918 (2024).","journal-title":"Cancer Res."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01550-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01550-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01550-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:50:45Z","timestamp":1791327045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01550-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1550"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01550-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"376"}}